neuropacs

Neuropacs operates at the intersection of medical imaging AI, digital diagnostics, and neurodegenerative disease research. Its differentiation is narrower than that of general-purpose radiology AI companies: the platform focuses on diffusion MRI, quantitative neurodegeneration measures, and disease-specific classification for Parkinsonian syndromes and dementia-related conditions. AIDP addresses differentiation among Parkinson’s disease, multiple system atrophy-parkinsonian type, and progressive supranuclear palsy, while AIDD targets Alzheimer’s disease dementia versus dementia with Lewy bodies. AIND adds a longitudinal index for tracking neurodegeneration and supporting clinical research. The company’s FDA De Novo classification on Apr 7, 2026 provides a regulatory milestone that distinguishes its Parkinsonian-syndrome offering from research-only imaging tools. Its claimed use of Free-Water Imaging, harmonized multi-site data, and PACS-compatible cloud workflows may also reduce implementation friction for healthcare providers and trial sponsors. Neuropacs therefore appears to be an early-stage, specialized entrant rather than an established broad-platform imaging vendor.

Neuropacs’ trajectory shows a progression from company formation in 2021 toward regulatory validation and broader clinical use cases in 2026. The January 2026 seed financing of $1 million, led by Neuro Investment Group, marked the clearest capital inflection point and was earmarked partly for recruiting. The April 2026 FDA De Novo classification moved the company’s Parkinsonian-syndrome software beyond a purely investigational positioning: the product became available as a prescription device intended to aid clinicians using standard 3T MRI systems. A June 2026 publication comparing the company’s imaging biomarker with a CSF alpha-synuclein assay added evidence-generation activity around clinical validity and disease characterization. Neuropacs is also building a product family spanning Parkinsonian-syndrome differentiation, dementia classification, longitudinal neurodegeneration measurement, diagnostics, and clinical-trial services. The disclosed team remains lean, with two current featured positions and an employee band of one to ten, so execution capacity and hiring will be important determinants of scale.